

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/105713/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Ramji, Dipak ORCID: <https://orcid.org/0000-0002-6419-5578>, Davies, Thomas, Gallagher, Hayley, Moss, Joe ORCID: <https://orcid.org/0000-0002-1866-9752>, Faizah, Jaffar and Al-Ahmadi, Wajdan 2016. Nutraceuticals as preventative and therapeutic agents in atherosclerosis. Journal of Clinical and Experimental Cardiology 7 (6) , p. 31. 10.4172/2155-9880.C1.029 file

Publishers page: <http://dx.doi.org/10.4172/2155-9880.C1.029>
<<http://dx.doi.org/10.4172/2155-9880.C1.029>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Annual Conference on

Atherosclerosis and Clinical Cardiology

July 11-12, 2016 Philadelphia, USA

Nutraceuticals as preventative and therapeutic agents in atherosclerosis

Dipak P Ramji, Thomas S Davies, Hayley Gallagher, Joe W E Moss, Faizah B Jaffar and Wijdan Al-Ahmadi
Cardiff University, UK

Atherosclerosis, an inflammatory disorder of the vasculature and the underlying cause of myocardial infarction and cerebrovascular accident, is responsible for more global deaths compared to any other disease. Although a slight reduction in morbidity and mortality from this disease has been achieved recently because of pharmaceutical intervention and lifestyle changes, this is expected to change in the future due to global increase in obesity and diabetes. Current pharmaceutical therapies against atherosclerosis are associated with a marked residual risk for cardiovascular disease together with other issues such as side effects and patient-dependent efficacy. In addition, many pharmaceutical agents have recently proved disappointing at the clinical level (e.g. agonists of peroxisome proliferator-activated receptors, inhibitors against cholesterol ester transfer protein and phospholipase A₂). It is therefore important to develop alternative therapies for the prevention and/or treatment of atherosclerosis. Interest in nutraceuticals as preventative/therapeutic agents in atherosclerosis has recently increased considerably and therefore necessitates an in-depth understanding of their actions together with the underlying mechanisms. We have recently investigated the effects of several nutraceuticals, including hydroxytyrosol and dihomogamma-linolenic acid, on several key monocyte/macrophage processes associated with atherosclerosis (e.g. monocytic migration, macrophage polarization, foam cell formation, activation of inflammasome and production of reactive oxygen species). These will be presented in the context of current therapies and those that are being developed.

Biography

Dipak P Ramji received his BSc (Hons.) degree (Biochemistry) and his PhD from University of Leeds. This was followed by Post-doctoral research at the EMBL (Heidelberg) and IRBM (Rome) with fellowships from the Royal Society and the EU. He joined Cardiff University in 1992 and is currently a Reader at Cardiff School of Biosciences. His research is focused on the impact of the immune and inflammatory responses on atherosclerosis with emphasis on the action of cytokines on macrophages. He has published over 80 peer-reviewed papers, reviews and book chapters. He is an Editorial Board Member of 16 international journals.

Ramji@cardiff.ac.uk

Notes: